Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis  by Adeboyeku, David et al.
Journal of Cystic Fibrosis 5 (2006) 261–263
www.elsevier.com/locate/jcfCase report
Open follow-up study of tobramycin nebuliser solution and colistin in
patients with cystic fibrosis☆
David Adeboyeku, Sandra Scott, Margaret E. Hodson⁎
Department of Cystic Fibrosis, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK
Received 24 February 2006; received in revised form 26 April 2006; accepted 10 May 2006
Available online 27 June 2006Abstract
A previous study of tobramycin nebuliser solution (TNS) compared with colistin [C] in cystic fibrosis (CF) patients, chronically infected
with pseudomonas, showed benefit for the TNS treated patients over one treatment cycle only. The current report is of an extension of that
study.
An open randomised cross-over study of TNS compared with C was conducted on 21 patients who had previously been on the 1 cycle
study. They continued for a further 5 months and then crossed over to the alternate treatment.
There was an advantage for TNS over C in FEV1 % predicted change over time. The C slope was −0.88% per month and the TNS slope
0.35% per month (p=0.0002). This suggests advantages of TNS over C in a study with a small number of patients. Larger studies are
required.
© 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Nebulised antibiotics; Tobramycin; Colistin1. Introduction
Pseudomonas aeruginosa is found frequently in the
respiratory tract of patients with cystic fibrosis (CF) [1–4].
On average patients lose 2% of their lung function per year
[5–7]. Acute exacerbations of infection are usually treated
with intravenous antibiotics [8,9]. However, regular neb-
ulised antibiotic treatment is used in an effort to maintain, or
even improve, lung function. In Europe colistin has often
been the nebulised antibiotic of first choice [10–14].
Tobramycin nebuliser solution (TNS) is a preservative
free formulation for nebulisation. Placebo controlled studies
have demonstrated significant improvement in lung function
within 10 days for TNS treated patients [15,16] and lung
function remained above baseline during long-term inter-
mittent treatment cycles (4 weeks on, 4 weeks off) for 18–☆ Study sponsored by Chiron Biopharmaceuticals, Cranford, Hounslow,
TW5 9RR.
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tobramycin compared with colistin of 1 month's duration
showed significant improvement with TNS but not with
colistin [17]. This report shows the effect of over a longer
period.
2. Methods
2.1. Patients
Patients who have participated in the randomised 1 cycle
study of TNS compared to C study were asked to participate
in this longer-term study. The patients who participated in
the extension study continued for another 5 months from the
last dose of drug on the previous study [17]. After a 2 week
wash out period they crossed over to be treated with the
other treatment for a further 5 months. Monthly FEV1 was
recorded, together with sputum samples, for organisms and
sensitivity. Patients were allowed to continue their routine,
recombinant human deoxyribonuclease (rhDNase). Patients
were excluded from the study if they had received anti-ed by Elsevier B.V. All rights reserved.
Fig. 1. Estimated FEV1 (% predicted) change based on repeated measure
ANOVA model.
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to the study or any other investigational drug within
4 weeks of initial study drug administration. Patients known
to be hypersensitive to aminoglycosides or polymixins,
those with significant haemoptysis, new changes on the
chest X-ray, pregnancy or impaired renal function were
excluded, as were patients who had grown B. cepacia.
2.2. Treatment regimen
Patients received either TNS 300 mg, 5 mL, (Tobramycin
solution for inhalation [TOBI®] Chiron, Hounslow, UK)
twice daily on alternate months, or Colistin sulphometho-
nate sodium (Colomycin ® injection, Pharmax Limited,
Kent, UK) 1 MU dissolved in 3 mL of preservative free
normal saline, by inhalation twice daily. After 5 months the
treatment was crossed over. The dose of colistin was
selected as the current practice in UK and Ireland. The TNS
was administered using a Para LC PLUS nebuliser (Pari
Medical Limited, West Byfleet, UK) and a CR50 compres-
sor (Medic Aid, Bognor Regis, UK). Colistin was
administered using a Ventstream nebuliser (Medic Aid)
and CR50 compressor (Medic Aid). Measurements of lung
function, microbiology, side effects, hospital admissions and
antibiotic treatment were recorded. The primary end point
for this study was the rate of change in lung function, %
predicted.
2.3. Statistical analysis
The data were analysed by repeated measure mixed effect
analysis of covariance [18]. The model contains baseline
effects (month 0), treatment effects (TNS and C), and time
(months) as fixed effects.
The study protocol was approved by the Hospital Ethics
Committee. Written consent was obtained from all patients.
3. Results
Ten patients were randomised to receive tobramycin and
eleven patients were randomised to receive colistin in the
first part of the study. 21 patients were randomised and 15
patients completed. Six patients withdrew from the study.
Two with tobramycin resistant pseudomonas, one withTable 1
Patient baseline demography
Treatment sequence
C–T T–C
N 11 10
Mean age (SD) 30.0 (11.9) 30.2 (6.9)
Males 8 4
Females 3 6
Mean weight kg (SD) 66.4 (11.4) 55.9 (5.25) p=0.02
Mean FEV1 % (SD) 58.3 (10.2) 41.6 (14.3) p=0.04anaphylaxis due to i.v. Ceftazidime for an exacerbation of
infection, three were non-compliant.
The results (Table 1 and Fig. 1) show an advantage of
TNS over colistin in terms of FEV1 % predicted change over
time. FEV1 during colistin treatment had a slope of −0.88%
per month, and during TNS a slope of 0.35% per month. This
difference in the month by month treatment effects of the two
antibiotics is highly significant (p=0.0002).
There were no statistically significant differences in the
number of days on intravenous or oral antibiotics, or quality
of life. Two patients developed tobramycin resistant P.
aeruginosa which was treated with intravenous and inhaled
colistin.
4. Discussion
This study indicates an advantage for TNS when com-
pared with colistin. If these results were to be confirmed in
a larger population then it would be of real clinical
importance. However the sample size was small, limited by
the availability of trial drugs and may have influenced the
results. It is important to note that the rate of decline of
lung function on colistin is greater than you would expect
in the UK population. These results should be regarded as a
pilot study and further studies in larger groups of patients
are essential.
Both nebuliser regimens were well tolerated by the
patients although one sicker patient could not tolerate the
month off Tobi. The logic of using TNS 1 month on and
1 month off is to reduce drug resistance. Perhaps patients
would benefit if the TNS was alternated with colistin as few
pseudomonads become resistant to this antibiotic. A longer-
term study is required with more patients to look at the effect
of TNS in the monthly on/off cycles compared with TNS
alternating with colistin.
In this medium-term study, the TNS solution signifi-
cantly improved lung function. Only longer studies will
show whether this treatment modifies the disease progres-
sion and improves survival. It would seem appropriate,
however, to advise clinicians that when a patient is not
doing well on inhaled colistin, it would be appropriate, if
the organisms were sensitive to tobramycin, to suggest a
change to TNS.
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